| Company Name: |
Shanghai Huzhen Industrial Co., LTD
|
| Tel: |
021-60345367 13916550749 |
| Email: |
sales@shzbio.com |
| Products Intro: |
Product Name:Bcl-2
Purity:> 99% Package:50ul/RMB 1580;100ul/RMB 2680 Remarks:Apoptosis regulator Bcl 2; Apoptosis regulator Bcl2; AW986256
|
| Company Name: |
ZSGB-BIO
|
| Tel: |
02-400-810-9781 400810978 |
| Email: |
sales@zsbio.com |
| Products Intro: |
Product Name:Bcl-2
|
| Company Name: |
IQ Products
|
| Tel: |
1-0031505757000 0031505757000 |
| Email: |
marketing@iqproducts.nl |
| Products Intro: |
Product Name:BCL-2
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Email: |
ordercn@merckgroup.com |
| Products Intro: |
Product Name:Anti-Phospho-BCL2-S70 antibody produced in rabbit
|
|
| Product Name: | Bcl-2 | | Synonyms: | ANTI-PHOSPHO-BCL-2(T56) antibody produced in rabbit;Anti-BCL2A1 antibody produced in rabbit;ANTI-BCL-2 (CENTER SER70) antibody produced in rabbit;ANTI-PHOSPHO-BCL-2(S70) antibody produced in rabbit;Anti-BCL2A1 antibody produced in goat;ANTI-BCL-2 (BH3 DOMAIN SPECIFIC) antibody produced in rabbit;Mouse Anti-Bcl-2 antibody;Recombinant Human Bcl-2 (1-218) | | CAS: | | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | proteins | | Mol File: | Mol File | ![Bcl-2 Structure]() |
| | Bcl-2 Chemical Properties |
| storage temp. | -20°C | | form | buffered aqueous solution | | biological source | rabbit |
| Hazard Codes | Xn | | Risk Statements | 22 | | WGK Germany | WGK 2 | | HS Code | 3504009000 | | Storage Class | 10 - Combustible liquids |
| | Bcl-2 Usage And Synthesis |
| Uses | Useful for the study of apoptosis, screening inhibitors and selectivity profiling. | | Biological Activity | The expression of BCL2A1 protein is regulated by NF-KB transcription factor. It has prosurvival and metastatic effects and facilitates survival of leukocytes subsets and inflammation. It is upregulated in melanomas and chronic inflammatory diseases. | | Pharmacology | BCL-2 has been characterized in SCLC via immunohistochemistry, microarray
detection of mRNA, genomic sequencing and proteomic profiling with levels up
to 84%. In preclinical models, BCL-2 binds and sequesters BH3-only proapoptotic proteins BID or BIM and prevents them from interacting with the pore-forming effectors that lead to apoptosis and cell death. Understanding of the mechanism of BCL-2
proteins has led to two approaches to inhibiting this pathway, either by direct inhibition of BCL-2 or using BH-3 mimetics.
ABT-263, a BH3 mimetic, demonstrated antitumor activity in laboratory models
of SCLC but unfortunately has not led to repeated success in the clinic.
Phase II trials of ABT-263 have not demonstrated success. Out of 26 patients, only
1 showed a response to treatment with ABT-263.
Venetoclax, an effective BCL-2 inhibitor which has been effective clinically in
treating a variety of hematologic malignancies, has also been investigated.
Preclinical data appears promising as venetoclax, dosed at 100mg/kg/qd, induced
tumor regression in mouse models, and further investigation is required. |
| | Bcl-2 Preparation Products And Raw materials |
|